MSLN and neoplasm: Its antitumor mechanism exhibits dual characteristics: On the one hand, it mediates antibody‐dependent cellular cytotoxicity (ADCC) by binding to MSLN, thereby activating immune effector cells such as NK cells to kill tumor cells; on the other hand, it competitively blocks the ligand‐receptor interaction between MSLN and MUC16 (CA125), thereby inhibiting tumor cell adhesion and metastatic behaviors [240].